Nervous system
Cholinesterase inhibitors (for dementia)
Drugs that slow the breakdown of acetylcholine in the brain, partly compensating for the loss of cholinergic neurons in Alzheimer disease; they modestly improve symptoms but do not stop the disease.
Mechanism of action
- Alzheimer disease destroys cholinergic neurons of the basal forebrain early, depriving the cortex and hippocampus of acetylcholine.
- Donepezil, rivastigmine and galantamine reversibly inhibit acetylcholinesterase in the brain (rivastigmine also butyrylcholinesterase).
- Acetylcholine lasts longer in the synapse, modestly improving memory and function for a time.
- They also act on peripheral cholinergic synapses: heart, gut and bronchi.
Molecular targets
- Acetylcholinesterase: Reversible inhibitor
Drugs in Cholinesterase inhibitors (for dementia)
- Donepezil (Once daily.)
- Rivastigmine (Also as a skin patch.)
- Galantamine
Therapeutic uses
- Mild to moderate, and with donepezil severe, Alzheimer disease
- Dementia in Parkinson disease (rivastigmine)
Diseases it treats
Adverse effects
- Nausea, vomiting, diarrhoea and weight loss
- Bradycardia and syncope
- Vivid dreams and insomnia
- Muscle cramps
Contraindications by condition
- Bradycardia or heart block (Use with care): Increased vagal tone slows the heart further and can cause fainting.
- Bronchial asthma (Use with care): Acetylcholine constricts the bronchi and increases secretions.
- Peptic ulcer disease (Use with care): Cholinergic stimulation increases gastric acid secretion.
Connected topics
Written from
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 8, Drugs for Neurodegenerative Diseases, Drugs used in Alzheimer disease
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 60, Special Aspects of Geriatric Pharmacology, Alzheimer disease
Educational reference. Not medical advice, diagnosis or treatment.